GSA Capital Partners LLP Purchases New Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

GSA Capital Partners LLP purchased a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 10,357 shares of the company’s stock, valued at approximately $246,000.

Other hedge funds have also recently bought and sold shares of the company. American International Group Inc. bought a new position in shares of LENZ Therapeutics during the first quarter worth approximately $44,000. SG Americas Securities LLC acquired a new position in LENZ Therapeutics in the 3rd quarter valued at $107,000. Squarepoint Ops LLC bought a new position in LENZ Therapeutics during the 2nd quarter worth $181,000. Rhumbline Advisers lifted its holdings in shares of LENZ Therapeutics by 265.6% during the second quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock worth $291,000 after buying an additional 12,214 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of LENZ Therapeutics by 28.4% during the second quarter. Renaissance Technologies LLC now owns 60,166 shares of the company’s stock worth $1,040,000 after buying an additional 13,300 shares in the last quarter. 54.32% of the stock is currently owned by institutional investors and hedge funds.

LENZ Therapeutics Price Performance

LENZ stock opened at $35.50 on Friday. The company’s 50-day moving average price is $27.29 and its two-hundred day moving average price is $22.54. LENZ Therapeutics, Inc. has a 12 month low of $14.42 and a 12 month high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. During the same quarter in the prior year, the firm earned ($1.33) earnings per share. On average, sell-side analysts expect that LENZ Therapeutics, Inc. will post -2.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LENZ has been the topic of a number of recent research reports. Raymond James assumed coverage on shares of LENZ Therapeutics in a research report on Friday, September 27th. They set an “outperform” rating and a $37.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of LENZ Therapeutics in a report on Thursday, November 7th. Piper Sandler reiterated an “overweight” rating and issued a $36.00 price target on shares of LENZ Therapeutics in a research report on Thursday, August 15th. Finally, William Blair raised LENZ Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $35.40.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.